{"download_date": ["ClinicalTrials.gov processed this data on May 09, 2023"], "link_text": ["Link to the current ClinicalTrials.gov record."], "url": ["https://clinicaltrials.gov/show/NCT05380986"], "org_study_id": ["SHR-1210-RWS"], "nct_id": ["NCT05380986"], "brief_title": ["Camrelizumab Combined With Apatinib Mesylate"], "official_title": ["A Real World Study of Camrelizumab Combined With Apatinib Mesylate in Solid Tumors"], "lead_sponsor": [], "source": ["Henan Cancer Hospital"], "has_dmc": ["No"], "is_fda_regulated_drug": ["No"], "is_fda_regulated_device": ["No"], "textblock": ["The purpose of this study is to observe the safety of camrelizumab combined with apatinib\r\n      mesylate in the treatment of solid tumors", "According to current studies, the combination of camrelizide and apatinib mesylate has\r\n      significant efficacy and controllable toxicity in the treatment of solid tumors.\r\n\r\n      This study adopted camrelizumab combined with apatinib mesylate in the treatment of solid\r\n      tumors, aiming to further explore the safety of camrelizumab combined with apatinib mesylate\r\n      in the treatment of solid tumors and provide more research data for the treatment of solid\r\n      tumors."], "overall_status": ["Recruiting"], "type": ["Anticipated", "Anticipated", "Anticipated", "Anticipated", "Actual", "Actual"], "start_date": ["May 20, 2022"], "completion_date": ["May 1, 2025"], "primary_completion_date": ["May 1, 2024"], "phase": [], "study_type": ["Interventional"], "has_expanded_access": ["No"], "allocation": [], "intervention_model": ["Single Group Assignment"], "primary_purpose": ["Treatment"], "masking": ["None (Open Label)"], "measure": ["AE", "Objective response rate", "Disease control rate", "Overall survival"], "time_frame": ["up to 2 years", "up to 2 years", "up to 2 years", "up to 2 years"], "description": ["any adverse medical event that occurs after a subject or clinical study receives a drug or treatment regimen", "Defined as the proportion of patients with a documented complete response, and partial response (CR+PR)", "defined as the proportion of patients with complete response, partial response and disease stabilization (CR+PR+SD)", "Overall survival", "Camrelizumab 200 mg, IVGTT D1, apatinib mesylate, once daily. The specific prescription is determined by the investigator. Continued use until disease progression, unacceptable toxicity, or withdrawal for other reasons.", "Camrelizumab 200 mg, IVGTT D1, apatinib mesylate, once daily. The specific prescription is determined by the investigator. Continued use until disease progression, unacceptable toxicity, or withdrawal for other reasons."], "number_of_arms": [1.0], "enrollment": [500.0], "condition": ["Solid Tumor"], "arm_group_label": ["Camrelizumab combined with apatinib mesylate", "Camrelizumab combined with apatinib mesylate"], "arm_group_type": ["Experimental"], "intervention_type": ["Drug"], "intervention_name": ["Camrelizumab combined with apatinib mesylate"], "criteria": [], "gender": ["All"], "minimum_age": ["18 Years"], "maximum_age": [], "healthy_volunteers": ["No"], "facility": [], "status": ["Recruiting"], "contact": [], "country": ["China"], "verification_date": ["May 2022"], "study_first_submitted": ["May 10, 2022"], "study_first_submitted_qc": ["May 15, 2022"], "study_first_posted": ["May 19, 2022"], "last_update_submitted": ["May 15, 2022"], "last_update_submitted_qc": ["May 15, 2022"], "last_update_posted": ["May 19, 2022"], "responsible_party_type": ["Principal Investigator"], "investigator_affiliation": ["Henan Cancer Hospital"], "investigator_full_name": ["LiNing"], "investigator_title": ["Associate Chief Physician"], "mesh_term": ["Apatinib"]}